Navigation Links
FDA Cancer Drug Approval Rate Highlighted in JNCI
Date:2/18/2010

Agency Analysis: More than 50 new cancer indications approved over a 32-month period

SILVER SPRING, Md., Feb. 18 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration's Office of Oncology Drug Products approved more than 50 new indications for the use of oncology and hematology drugs and biologics between July 2005, when the office began reviewing marketing applications, and the end of 2007, according to a new agency study.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

During the time period, the office reviewed 60 applications from companies seeking approval to treat people with 30 different types of cancer, including breast, lung, colon, kidney, head and neck and several forms of blood cancer.

The Office of Oncology Drug Products, part of the Center for Drug Evaluation and Research (CDER), took action on 58 of the applications, approving 53 new cancer indications. Five applications were not approved, and two applications were withdrawn before any regulatory action was taken. These approved applications included indications for 18 new drugs that had not been previously approved and 35 additional indications for already approved drugs.

"Our reviews during this period focused on approving new or existing treatments based on treatment effect, patient safety, and the treatment's risk-benefit profile," said Rajeshwari Sridhara, Ph.D., lead author of the FDA analysis.

"We also considered the patient populations in need of additional treatment options, existing treatments, and whether this was a new molecular entity," said Sridhara, an acting division director, in CDER's Office of Biostatistics.

The FDA's retrospective analysis appears in the Feb. 24, 2010, issue of the Journal of the National Cancer Institute. The journal article is available now at http://jnci.oxfordjournals.org.

Approval data from July 1, 2005 through Dec. 31, 2007 were reviewed by the authors for this analysis. This review was started after the formation of the Office of Oncology Drug Products and the implementation in 2007 of the Food and Drug Administration Amendments Act (FDAAA). The review included indications for both conventional oncology drugs and biological oncology products reviewed in CDER. It did not include products reviewed in other FDA centers.

"The FDA used a variety of trial designs and endpoints in approving these applications. In addition, we implemented recent regulatory initiatives including accelerated approval and priority reviews to expedite the approval of these indications," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products, and one of the review's co-authors.

The accelerated approval process allows for earlier approval of drugs to treat serious diseases with an unmet medical need and is based on a surrogate endpoint, a laboratory measurement or physical sign that is used in clinical trials as an indirect measurement of clinical benefit. Under an accelerated approval, the FDA approves the drug on the condition that the drug manufacturer conducts further studies to evaluate the drug's actual clinical benefit. Priority reviews are conducted within six months, whereas other reviews are usually reviewed in 10 months.

Other highlights from the cancer drug approvals review include:

  • New treatments were approved for six of the seven most deadly forms of cancer in the United States (lung, colon, breast, ovarian, cervical and pancreatic)
  • 35 of the approvals were existing products seeking new treatment indications
  • New molecular entities represented 18, or 34 percent, of the 53 approvals
  • Approvals included treatments for pediatric patients, supportive care indications aimed at improving the side effects of cancer therapies, and treatment options for rare diseases  
  • Three new treatments were approved for advanced kidney cancer
  • Nine drugs received accelerated approval, a regulatory mechanism allowing the FDA to approve a drug with subsequent studies performed after approval to demonstrate an effect on survival or other clinically meaningful endpoints
  • Twenty five percent of the indications approved were based on improvement in overall survival or improvement in both progression-free survival and overall survival

Other authors of the review include: John R. Johnson, M.D., Clinical Team Leader, Robert Justice, M.D., director of the Division of Drug Oncology Products, Patricia Keegan, M.D., director of the Division of Biologic Oncology Products and Aloka Chakravarty, Ph.D., acting division director, Division of Biometrics VII, Office of Biostatistics.

For more information:

FDA Office of Oncology Drug Products

http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

Food and Drug Administration Amendments Act (FDAAA)

http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/default.htm

Journal of the National Cancer Institute

http://jnci.oxfordjournals.org

Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

Back to top

RELATED LINKS
http://www.fda.gov/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Scientists Spot Genetic Fingerprints of Individual Cancers
2. DASH FOR DAD Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
3. Dolphins could be ideal model to study human cervical cancer, UF veterinarians say
4. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
5. Personalizing cancer: Creating biomarkers from tumor DNA
6. Chemical tags likely to affect metabolism, cancer development
7. FDA Approved Diabetes Drug Despite Hints at Cancer Risk
8. VARI findings may help patients with deadly kidney cancer
9. Drug for advanced kidney cancer shrinks tumors prior to surgery
10. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
11. Researchers chart genomic map spanning over 2 dozen cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... ... Dickinson Insurance & Financial Services continues their commitment to act as Agents ... local boy named Barrett, who has been fighting ALL leukemia for almost two years. ... all local families dealing with childhood cancer. Information on how to help is now ...
(Date:2/11/2016)... ... 2016 , ... Be Well Medical Group (Be Well) is pleased ... at 108 South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is ... the convenience of their homes, offices or at the practices’ local office. It is ...
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has completed ... CA, on February 6th & 7th, 2016 according to kicking coach Michael Husted. , ... invited to the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... in significantly higher rates of several common cancer screenings, especially among women. Cancer ... outcomes and survival rates. , The study,“What Does Medicaid Expansion Mean for ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the World Molecular Imaging Congress (WMIC), will be held in New York City, ... is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial ... --> --> Financial ... $9.45 billion, up 28% on a constant currency basis ... billion. Excluding the impact of the acquisition of Abbott ... (the "EPD Business"), full year adjusted total revenues increased ...
(Date:2/10/2016)... February 10, 2016 A new report from business intelligence ... states that the Alzheimer,s disease market will more than double from just under ... Compound Annual Growth Rate (CAGR) of 11%. Canada , ... , Spain , the UK, and Japan ... forecast period. --> Canada , France ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... viral gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical ... and other chronic diseases, have entered into a Manufacturing ... produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in ... --> This relationship will leverage Lonza,s ...
Breaking Medicine Technology: